Edition:
United States

Thrombogenics NV (THR.BR)

THR.BR on Brussels Stock Exchange

3.58EUR
22 Sep 2017
Change (% chg)

€-0.07 (-1.86%)
Prev Close
€3.65
Open
€3.67
Day's High
€3.70
Day's Low
€3.56
Volume
51,809
Avg. Vol
40,871
52-wk High
€4.08
52-wk Low
€2.50

Chart for

About

ThromboGenics NV is a Belgium-based biopharmaceutical company, which focuses on the development and commercialization of ophthalmic medicines. The Company’s lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was... (more)

Overall

Beta: 0.83
Market Cap(Mil.): €129.29
Shares Outstanding(Mil.): 36.09
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 81.40 16.08
EPS (TTM): -- -- --
ROI: -- 3.18 14.60
ROE: -- 4.93 14.03

BRIEF-Thrombogenics regains global rights to Jetrea

* THROMBOGENICS NV : THROMBOGENICS REGAINS GLOBAL RIGHTS TO JETREA (OCRIPLASMIN)

Sep 18 2017

Swiss stocks - Factors to watch on Sept 18

ZURICH, Sept 18 The Swiss blue-chip SMI was seen opening 0.3 percent higher at 9,054 points on Monday, according to premarket indications by bank Julius Baer .

Sep 18 2017

BRIEF-Thrombogenics H1 operating loss flat at 15 million euros

* ‍FOR FIRST HALF OF 2017, THROMBOGENICS REPORTED A NET LOSS OF EUR 15.2 MILLION, OR EUR 0.42 PER SHARE​

Sep 07 2017

BRIEF-Oncurious acquires unique portfolio of immuno-oncology assets from VIB

* ONCURIOUS NV ACQUIRES UNIQUE PORTFOLIO OF NEXT-GENERATION IMMUNO-ONCOLOGY ASSETS FROM VIB

Sep 01 2017

BRIEF-Bioinvent and ThromboGenics amending long-standing monoclonal antibody development agreement

* Bioinvent and ThromboGenics amending long-standing monoclonal antibody development agreement

Jul 10 2017

BRIEF-Bioinvent and Thrombogenics amend monoclonal antibody development agreement

* BIOINVENT AND THROMBOGENICS AMENDING LONG-STANDING MONOCLONAL ANTIBODY DEVELOPMENT AGREEMENT

Jul 10 2017

BRIEF-Thrombogenics says Thomas Clay appointed chairman board of directors

* THROMBOGENICS LONG-TIME NON-EXECUTIVE DIRECTOR THOMAS CLAY APPOINTED CHAIRMAN OF THE BOARD OF DIRECTORS

Jun 15 2017

BRIEF-Thrombogenics cash and investments at end of March EUR 73.3 mln

* CASH AND INVESTMENTS WERE EUR 73.3 MILLION AS OF END OF MARCH 2017, COMPARED WITH EUR 80.1 MILLION AT END OF DECEMBER 2016

May 11 2017

BRIEF-New Thrombogenics ophthalmic research findings presented at ARVO 2017

* New Thrombogenics ophthalmic research findings presented at ARVO 2017 annual vision research meeting in Baltimore

May 02 2017

BRIEF-Thrombogenics achieves important milestone in development of THR-149, novel plasma kallikrein inhibitor for diabetic macular edema

* Achieves important milestone in the development of THR-149, a novel plasma kallikrein inhibitor for diabetic macular edema

Apr 20 2017

Earnings vs. Estimates